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Abstract
PURPOSE: Ultrasound elastography is a new imaging technique that can be used to assess tissue stiffness. The
aim of this study was to investigate the potential of ultrasound elastography for monitoring treatment response of
locally advanced breast cancer patients undergoing neoadjuvant therapy. METHODS: Fifteen women receiving
neoadjuvant chemotherapy had the affected breast scanned before, 1, 4, and 8 weeks following therapy initiation,
and then before surgery. Changes in elastographic parameters related to tissue biomechanical properties were
then determined and compared to clinical and pathologic tumor response after mastectomy. RESULTS: Patients
who responded to therapy demonstrated a significant decrease (P < .05) in strain ratios and strain differences
4 weeks after treatment initiation compared to non-responding patients. Mean strain ratio and mean strain differ-
ence for responders was 81 ± 3% and 1 ± 17% for static regions of interest (ROIs) and 81 ± 3% and 6 ± 18% for
dynamic ROIs, respectively. In contrast, these parameters were 102± 2%, 110± 17%, 101± 4%, and 109± 30% for
non-responding patients, respectively. Strain ratio using static ROIs was found to be the best predictor of treatment
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response, with 100% sensitivity and 100% specificity obtained 4 weeks after starting treatment. CONCLUSIONS:
These results suggest that ultrasound elastography can be potentially used as an early predictor of tumor therapy
response in breast cancer patients.
Translational Oncology (2013) 6, 17–24
Introduction
Breast cancer is the most frequent type of cancer diagnosed in
women, excluding cancer of the skin. An estimated number of
226,870 new cases of invasive breast cancer are expected to occur
among women in the United States during 2012 [1]. Approxi-
mately 5% to 20% of the cases diagnosed each year will present
with locally advanced breast cancer (LABC) [2,3]. LABC is usually
defined as stage III or inoperable disease. It typically includes tumors
>5 cm and/or involving the skin or chest wall, with or without
clinical nodal involvement. LABC is frequently characterized by a
much poorer prognosis compared to early-stage breast cancer. In
addition to its high rate of its loco-regional recurrence (10–20%),
only 55% of LABC patients survive at 5 years because of the high
risk for metastatic spread [2].
Current methods for LABC treatment include neoadjuvant che-
motherapy followed by mastectomy with axillary nodal clearance.
The surgery can be also followed by radiation therapy and possibly
Herceptin and/or hormonal manipulation, if indicated [4,5]. Several
investigations have reported the importance of clinical/pathologic
complete response to neoadjuvant chemotherapy as a factor in im-
proved treatment outcomes, resulting in survival rates up to 70%
[6–8]. However, this prognostic factor is assessed at the time of
surgery, where the window for optimizing a neoadjuvant treatment
is closed. Standard clinical measures based on anatomic information
from physical assessment, mammography, and conventional B-mode
ultrasound are often unable to objectively evaluate treatment response
early during the treatment period since functional changes related to
microscopically evident tumor death may precede macroscopic ana-
tomic changes. Recent studies have highlighted the importance of early
detection of patients refractory to neoadjuvant chemotherapy, as it
has been demonstrated that early salvage treatment for chemotherapy-
resistant tumors with radiation and surgery can result in a survival rate
of 46% at 5 years [9]. Therefore, imaging for early probing of the
extent of therapy response is crucial [10]. An objective low-cost func-
tional imaging method capable of assessing tumor response to guide
the personalization and optimization of neoadjuvant therapy would
be very useful and permit therapy changes to be made as needed when
faced with a lack of tumor response.
Ultrasound elastography is a recently developed dynamic imag-
ing technique that has been established as a promising modality to
identify relative tissue stiffness by measuring the degree of strain-
related distortion under the application of an external force [11–
16]. In this context, elastography consists of applying quasi-static
pressure on the examined tissue surface periodically and estimating
the induced strain distribution by tracking tissue motion. For this
purpose, raw ultrasound data consisting of radiofrequency data are
acquired continuously, and elastograms are generated by estimating
the strain evident between sequential frames [12,17]. Ultrasound
elastography inherits the advantages of ultrasound imaging such as
low cost, rapid imaging speed, portability, and high resolution and
is finding clinical use.
Ultrasound elastography has been demonstrated as capable of
detecting tumors and distinguishing between different types of
abnormalities, e.g., benign versus malignant lesions, in breast tissue
[14,18], thyroid tissue [13], prostate [19,20], and lymph nodes
[21]. One major advantage of ultrasound elastography over other
conventional contrast-enhanced imaging modalities is that no
contrast agent injection is needed in this modality. This is because
of the fact that the differentiable elasticity and stiffness, as main
sources of image contrast, are caused by changes in the physical
properties of the examined tissue. Ultrasound elastography has also
been applied for treatment monitoring of ablative therapies where
heating tissue induces a denaturation of proteins, which in turn
elevates the stiffness of ablated tissue [20,22,23]. Similarly, other
methods of cell death induction such as chemotherapy can sub-
stantially alter the biomechanical properties of the malignant tis-
sues during a course of treatment. This is mainly due to the fact
that tumor formation and its degeneration in response to treatment
exhibits considerable interactions, e.g., fibrosis and inflammation,
with stromal cells [24,25] that may change the biomechanical
properties with stromal cells. On this basis, ultrasound elastography
was investigated here as a method that may potentially provide
large contrast between treatment responding and non-responding
malignant tissues, early (a few weeks) following the start of neo-
adjuvant chemotherapy.
This study investigated for the first time, the application of
ultrasound elastography in monitoring chemotherapy response
for cancer treatment. A clinical evaluation was carried out to eval-
uate the efficacy of ultrasound elastography parameters for dis-
tinguishing between clinically and pathologically responding and
non-responding patients, early after treatment initiation. Fifteen
patients with LABC received neoadjuvant chemotherapy, as
“up-front” treatment, followed by mastectomy and axillary nodal
clearance. Data collection consisted of acquiring tumor ultrasound
images and elastography data before neoadjuvant treatment onset
and then at four times during treatment (weeks 1, 4, and 8, and
preoperatively). Clinical examinations were also conducted at each
follow-up time, where the tumor size was measured. Pathology
examinations were performed on resected specimens after mastectomy
using three-dimensional whole-mount histopathology [26], and data
on size, grade, histologic subtype, and tumor response were recorded.
Relative changes in the ratio of tumor to normal tissue stiffness were
calculated and monitored following treatment onset, compared to the
pretreatment data. Obtained results demonstrate the potential of ultra-
sound elastography techniques for predicting chemotherapy response,
as early as 4 weeks after treatment initiation.
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Materials and Methods
Study Protocol
The study included 15 patients with LABC and was carried out in
accordance with research ethics guidelines. Before treatment adminis-
tration, all patients were investigated using standard clinical imaging
and disease biopsied to confirm a cancer diagnosis. Ultrasound B-mode
and elastography data were acquired from the affected breast at the fol-
lowing times: before treatment, 1 week, 4 weeks, and 8 weeks following
the initiation of treatment, and before surgery. Clinical examinations
were also carried out before each imaging session, in addition to regular
patient visits. As part of clinical care, tumor magnetic resonance imag-
ing (MRI) using a 1.0-Tesla device (GE Healthcare, Waukesha, WI)
was conducted at the time of diagnosis and immediately before surgery
to measure tumor size. Following surgery, patient mastectomy speci-
mens were examined by a board-certified pathologist using whole-
mount [26] 5 in. × 7 in. pathology slides digitized using a confocal
scanner (TISSUEscope; Huron Technologies, Waterloo, ON) at 2-μm
resolution. Information regarding tumor grade, histologic subtype,
size, and treatment response was recorded. Patients were categorized as
having either a poor pathologic response or a good response. As defined
in previous studies [27–29], a patient was considered a good responder if
they had a 50% or more decrease in the tumor size in comparison to
pretreatment size along with a tumor cellularity decrease. A poor re-
sponder meant a <50% reduction in tumor size or unchanged disease
or an enlargement in tumor size compared to the size before treatment.
Instrument
Conventional B-Mode and elastography ultrasound data were
acquired using a Sonix RP System (Ultrasonix, Vancouver, Canada)
using a 6-cm-wide L14-5 transducer pulsed at 10 MHz at a rate of
12 frames per second. All the ultrasound data in this study were col-
lected by the same sonographer following standardized protocols for
data acquisition. For each patient, the transducer focus was set at a
tumor center depth and kept consistent throughout the study. Ultra-
sound B-mode and elastography scan planes of the tumor were ac-
quired in 1-cm increments under the guidance of a physician. On
average, five scan planes were acquired at a given evaluation. The re-
sulting elastography images were displayed using a 256-color map of
strain using a scale from red (highest strain, soft) to blue (low strain,
hard). Raw data were saved digitally for data analysis.
Data Analysis and Statistics
For each scan, the tumor region was identified using B-mode
images under the guidance of a physician and two types of tumor re-
gion of interest (ROI) were defined: static and dynamic. Static ROIs
were chosen to be rectangular in shape, encompassing the majority of
the tumor area in cross-section images. The size of these ROIs re-
mained constant throughout the study for a given patient. Dynamic
ROIs were selected to conform to the tumor by using a low-pass fil-
tered threshold method to detect the tumor edge in the pretreatment
scan and they were adjusted for subsequent scans depending on the
shape and size of the tumor. For each scan, static and dynamic B-mode
ROIs were also chosen for normal tissue as a comparison. These were
located at the same depth as their corresponding tumor ROIs. B-mode
ROIs were co-registered with the elastography maps. Mean strains
within the tumor ROIs and its surrounding normal tissue ROIs were
calculated by averaging data in selected areas for static and dynamic
ROI analyses. Strain ratios were obtained by dividing the normal tissue
strain by the tumor strain. These ratios were subsequently averaged for
each patient’s tumor at a given assessment time to obtain the strain ratio
of each scan. Similarity, strain differences (by subtraction) between the
tumor and its surrounding normal tissue were obtained for each scan.
Changes in the values from baseline (pretreatment) between respond-
ers and non-responders at each time point for each elastography parameter
were compared independently. Statistical analysis using a t test (two-sided,
95% confidence) was carried out to assess if patients showing statistically
significant changes in elastography parameters at weeks 1 and 4 correlated
to patient population demonstrating treatment response. Discriminant
analysis (PASW Statistics 18; SPSS, Inc, Chicago, IL) was used to deter-
mine which elastography parameter discriminate between responders and
non-responders at weeks 1 and 4. The changes in the values of strain ratio
and strain difference were used as predictors in the analysis, which exam-
ined the best separation between the two groups. Sensitivity and specificity
were calculated to measure the performance of the classification method in
terms of discriminating responders from non-responders. These were
calculated for both static and dynamic ROI methods of data analysis.
Results
Patient and Tumor Characteristics
Patient physical, tumor, and treatment characteristics are given in
Table 1. The mean patient age was 45 years (SD = 7; range, 34–55)
Table 1. Patient Characteristics.
Patient No. Age Menopausal Status Pretreatment Tumor Dimension (AP × ML × SI) in cm Histology Grade ER/PR Her-2–neu Neoadjuvant Treatment
1 55 N/A 5.4 × 5 × 2.3 Ductal N/A − + FEC + paclitaxel, trastuzumab
2 53 N/A 7.4 × 7 Ductal 2 + + Epirubicin, docetaxel
3 41 Premenopausal 4 Ductal 3 + + Docetaxel, carboplatin, trastuzumab
4 46 N/A 7 × 8 Ductal 3 − − AC + paclitaxel
5 33 Premenopausal 5.4 × 5 × 8 Ductal N/A + + AC + docetaxel, paclitaxel, trastuzumab
6 48 Postmenopausal 4.9 × 4.9 × 4.1 and 3.2 × 1.3 × 2.9 Ductal 2 + − AC + docetaxel
7 36 Premenopausal 4.4 × 3.9 × 5.8 Ductal N/A + − AC + paclitaxel
8 40 Premenopausal 4.4 × 3.4 Ductal 3 − − AC + paclitaxel
9 38 Premenopausal 7.5 × 4.9 × 9.2 Ductal 2 + − AC + paclitaxel
10 53 N/A 8.4 × 9.4 × 12.7 Metaplastic 3 − − AC + cisplatinum, gemcitabine platinum
11 50 Premenopausal 13 × 11 Ductal N/A − − AC + paclitaxel
12 49 Premenopausal 7.1 × 5.5 × 8.9 Ductal N/A − + Docetaxel, trastuzumab
13 40 Premenopausal 3 × 2.4 × 3 Ductal 3 + + AC + paclitaxel, trastuzumab
14 52 Premenopausal 4.1 × 3 × 2.5 Ductal N/A + − AC + paclitaxel, docetaxel
15 47 Premenopausal 6.3 × 4.1 × 7.4 Ductal 3 − + AC + paclitaxel, trastuzumab
AC indicates adriamycin and cytoxan; FEC, 5-fluorouracil, epirubicin and cyclophosphamide.
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and 10 patients were premenopausal. The average maximum tumor
size was 7.3 cm (SD = 3.0; range, 3–13). Fourteen patients had inva-
sive ductal carcinoma, one had metaplastic carcinoma, eight patients
were estrogen (ER)/progestron (PR) positive, seven were Her-2–neu
positive, three patients had grade 2 tumors, and six had grade 3 tumors.
Patients had a variety of neoadjuvant treatment plans with 80% of
patients receiving combined anthracycline and taxane–based chemo-
therapy. One patient received docetaxel, carboplatin, and trastuzumab,
and another received adriamycin and cytoxan with cisplatinum and
gemcitabine platinum chemotherapy. One patient received docetaxel
and trastuzumab chemotherapy.
Clinical and Pathologic Assessment of Tumor Response
LABC pathology specimens were examined in the same manner
by a board-certified pathologist ( J.Z.) to determine tumor response
(Table 2). Patients 1, 5, 6, 8, 11, 12, 13, 14, and 15 were classified
as good responders because of the absence of tumor or presence of
only minimal invasive disease. Patients 3, 4, 7, 9, and 10 had a poor
pathologic response. Their tumor sizes slightly changed compared to
their pretreatment size. Patient 2 was an exceptional case in that
pretreatment MRI indicated an invasive ductal carcinoma measur-
ing 7.4 [anterior-posterior (AP)] × 7 [medial-lateral (ML)] cm. After
treatment, the pathologic tumor size slightly decreased and measured
Table 2. Patient Pathologic Response Results.
Patient No. Posttreatment Tumor Dimensions (AP × ML × SI) in cm Notes Pathologic Response
1 N/A Complete pathological response Good
2 7 × 5 × 3 Carcinoma with mucinous features; very low cellularity Good
3 2.7 × 2.5 × 2.4 Tumor cellularity remains very high Poor
4 6.4 × 3.5 × 3 Large tumor volume remaining Poor
5 N/A Complete pathological response Good
6 1.4 × 1 × 1 Small volume of invasive tumor remaining Good
7 11.4 Extensive residual disease Poor
8 N/A No residual carcinoma Good
9 6.5 × 3 × 7.3 Invasive ductal carcinoma remaining Poor
10 all the breast Residual tumor took up all the breast; no response Poor
11 4 Good response Good
12 2 × 1.5 × 1 Complete response with only in situ disease Good
13 N/A No residual invasive carcinoma Good
14 N/A No residual invasive carcinoma Good
15 N/A No residual invasive carcinoma Good
Figure 1. Representative ultrasound B-mode and elastography images for (A) non-responder and (B) responder patients acquired before
treatment, at week 1, week 4, week 8, and preoperatively. The color bar shows tissue softness. Scale bar indicates 1 cm.
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7 (AP) × 5 (ML) × 3 [superior-inferior (SI)]. However, the residual
mass was composed of very large pools of extracellular mucin. Tumor
cells were very infrequent on examination, and thus tumor cellularity
was very low. Although the remaining pathologic tumor size was large,
the appearance of decreased tumor cellularity indicated a good response.
Ultrasound Elastography Assessment of Treatment Response
Tumors were easily identified from ROI placement on the basis of
their hypoechogenicity and lack of normal typical breast structure.
Before starting treatment, responders and non-responders demon-
strated similar tumor stiffness, with average strain ratios of 1.29 ±
0.04 and 1.26 ± 0.11, respectively. Non-responders typically revealed
no change in tumor elasticity during treatment for several weeks
(average strain ratios of 1.25 ± 0.11, 1.28 ± 0.09, and 1.23 ± 0.11
at weeks 1, 4, and 8, respectively). In contrast, responders indicated
visibly detectable changes in tumor stiffness (average strain ratios of
1.19 ± 0.04, 1.04 ± 0.04, and 1.04 ± 0.05 at weeks 1, 4, and 8,
respectively). Non-tumor breast tissue showed no changes in elastic-
ity during treatment. Representative ultrasound B-mode and elasto-
graphy images for a non-responder and a responder acquired before
treatment, at week 1, week 4, week 8, and preoperatively are pre-
sented in Figure 1. Representative quantitative data for the same pa-
tients and whole-mount histopathology are presented in Figure 2.
In the non-responding patient’s pathology, a large mass of residual
carcinoma was present at low and high magnifications. In the re-
sponding patient, minimal residual disease was detected with areas
demonstrating low cellularity. Figure 3 demonstrates average changes
in strain ratios and strain differences between non-responders and
responders using both static and dynamic ROIs. Table 3 presents
averaged strain ratios and averaged strain differences 1 and 4 weeks
after treatment initiation. Averaged strain ratios and strain differences
for non-responders and responders using static ROIs were extremely
(P < .001) and highly (P = .001) significant 4 weeks after treatment
initiation, respectively. There was no significance at 1 week after the
start of treatment. Non-responders and responders were found to be
highly significantly different 4 weeks after treatment initiation for
averaged strain ratios and strain differences using dynamic ROIs
(P = .002 and P = .008), respectively. There was no significance at
1 week after the start of treatment. Sensitivity and specificity analysis
results are also presented in Table 3. The best predictor of treatment
response was strain ratio using static ROIs, where 100% for both
sensitivity and specificity were achieved 4 weeks after treatment ini-
tiation. This was followed by the strain difference using static ROIs
and the strain ratio using dynamic ROIs (sensitivity, 89%; specific-
ity, 100%). Strain difference using dynamic ROIs was also found to
be a good predictor of therapeutic response (sensitivity, 89%; spec-
ificity, 80%) 4 weeks after treatment initiation.
Discussion
Ultrasound elastography is an emerging imaging modality that provides
information regarding tissue stiffness. It is non-invasive, portable, and
less expensive than other imaging modalities such as MRI or computed
tomography (CT). It does not involve the use of exogenous contrast
agents, which makes it ideal for multiple scans typically required for
treatment monitoring. Previous studies have demonstrated that this
modality may be used to monitor the treatment response of ablative
therapies [20,23]. Ultrasound-based elastography was shown to accu-
rately depict thermal lesions after radiofrequency ablation therapy in
Figure 2. Representative quantitative data for patients presented in Figure 1 ((A) non-responder; (B) responder) whole-mount histopathology.
The graphs illustrate the percentage change frompretreatment in elastographic parameters plotted over time. In the non-responding patient’s
pathology, a large mass of residual carcinoma is present at low and highmagnifications. In the responding patient, minimal residual disease
is visualized with areas demonstrating low cellularity. Scale bars indicate 5 and 0.2 mm in the low and high magnifications, respectively.
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porcine liver in vivo [23]. Specifically, in a study of 29 patients with
prostate cancer, elastography was successfully used to visualize thermal
lesions of the prostate in vivo, during and after high-intensity focused
ultrasound (HIFU) treatment [20]. In these patients, the prostate
appeared stiffer after treatment and a 40% to 60% decrease in average
strain was obtained compared to pretreatment measurements.
In this study, we report for the first time the results of 15 patients
with LABC receiving neoadjuvant chemotherapy whose tumor re-
sponses were monitored using ultrasound elastography. Strain ratios
and strain differences in responders exhibited a decrease during the
first weeks of the treatment (Figures 1–3). Using a static ROI analysis,
the mean strain ratio and strain difference for responders was 81 ± 3%
Figure 3. Changes in strain ratio and strain difference measured in non-responders (NR) and responders (R) using (A) static ROI and
(B) dynamic ROI methods. The graphs illustrate elastography parameters plotted as a percentage change from pretreatment for non-
responders versus responders over time. All differences were statistically significant (P < .05) at 4 weeks after treatment initiation. Error
bars represent ±1 SE.
Table 3. Discriminant Analysis at (A) 1 Week and (B) 4 Weeks after Treatment Initiation.
Parameter Non-responders Mean ± SE (%) Responders Mean ± SE (%) P value Sensitivity (%) Specificity (%)
(A)
Strain ratio (static) 99 ± 3 94 ± 5 .4 44 60
Strain difference (static) 90 ± 18 65 ± 15 .3 44 60
Strain ratio (dynamic) 97 ± 2 95 ± 5 .8 56 60
Strain difference (dynamic) 77 ± 15 74 ± 16 .9 44 60
(B)
Strain ratio (static) 102 ± 2 81 ± 3 .0003* 100 100
Strain difference (static) 110 ± 17 1 ± 17 .001† 89 100
Strain ratio (dynamic) 101 ± 4 81 ± 3 .002† 89 100
Strain difference (dynamic) 109 ± 30 6 ± 18 .008† 89 80
Percentages show the current values of parameters relative to the pretreatment. All strain ratios and strain differences for non-responders and responders were statistically significant 4 weeks after treatment
initiation. There was no statistical significance at 1 week after the start of treatment.
*Extremely significant (P < .001).
†Statistically highly significant (P < .01).
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and 1 ± 17% versus non-responders who exhibited values of 102 ± 2%
and 110 ± 17% at 4 weeks after treatment initiation, respectively.
These differences between responders and non-responders were found
to be statistically significant (P < .05). The use dynamic ROIs led to
similar findings; the mean strain ratio and strain difference for re-
sponders was 81 ± 3% and 6 ± 18% versus non-responders of 101 ±
4% and 109 ± 30%, respectively. These differences between responders
and non-responders were also found to be statistically significant (P <
.05) and provide further evidence on the use of ultrasound elastography
for monitoring treatment response in LABC patients. As the tumor
begins to respond to the treatment in responding patients, it begins
to become less stiff as a result of the changes in its structure and bio-
mechanical properties. This then leads to an increase in the tumor
strain and, hence, a decrease in the strain ratio and strain difference.
Patient 2 was an exceptional case and a data outlier. This 53-year-
old female was diagnosed with ductal carcinoma measuring 7.4 cm ×
7 cm (AP × ML). She was treated with epirubicin and docetaxel che-
motherapy. After surgery, her residual mass measured 7 cm × 5 cm ×
3 cm (AP × ML × SI) but only had mucinous features remaining
with very low tumor cellularity and this patient’s clinical response
was pathologically rated as good. However, the analysis of the elasto-
graphy data showed similar trends to those of non-responding patients.
This implies that the tumor strain remained unchanged during the
treatment. This finding is not surprising because, for this particular pa-
tient, the biomechanical properties of the tumor remained unaffected
due to the abundance of extracellular mucin. For this tumor subtype,
ultrasound elastography may not be sensitive or specific. However, this
will not likely cause any major limitation to this imaging modality
because mucinous tumors are rare, representing 1% to 4% of all breast
cancers [30].
The use of static ROIs for strain estimation was found to be supe-
rior to using dynamic ROIs because it permitted the distinction be-
tween responders and non-responders as early as 4 weeks after
treatment initiation when using strain ratio (estimated sensitivity,
100%; estimated specificity, 100%) and strain difference (estimated
sensitivity, 89%; estimated specificity, 100%) as predictors of treat-
ment response (Table 3). Static ROIs were rectangular with constant
size and included peritumoral regions in addition to the tumor, con-
trary to dynamic ROIs that only included tumor areas. The concur-
rent changes in the peritumor and tumor stiffness as a result of the
neoadjuvant treatment has likely contributed to the increased sensi-
tivity of this technique when using static ROIs in comparison with
dynamic ones. Another advantage of static ROIs is that they only need
to be defined once for a given patient after the initial scan and they
can be further used in subsequent scans without the need for tumor
segmentation. This makes the ultrasound elastography technique read-
ily feasible for breast cancer treatment monitoring.
Other methods have been devised for therapy response monitoring
including optical spectroscopy [27–29], new MRI methods for cell
death detection [31,32], and spectroscopic ultrasound for cell death
detection [33] and are reviewed elsewhere [34,35]. Such methods are
not generally used clinically. Shear wave imaging is similar to elasto-
graphy in that tissue stiffness measurement can be carried out quan-
titatively, which estimate the Young’s modulus of tissue [36,37].
Another method, acoustic radiation force impulse imaging, provides
an alternative method of estimating tissue stiffness [38,39]. Both
potentially can be used for therapy response monitoring.
In conclusion, this study demonstrates for the first time that ultra-
sound elastography technique may be used to discriminate between
clinically responding or non-responding patients early during the
course of neoadjuvant treatment. Results reported in this study indi-
cate that changes in ultrasound elastography parameters of treated
breast tumors strongly correlated with the clinical and pathologic re-
sponse of patients. These findings pave the way for establishing proto-
cols for the clinical applications of ultrasound elastography techniques
in therapy response monitoring of breast cancer patients. Such proto-
cols are required for the enhancement of personalized cancer therapy in
which patients are switched from ineffective therapies to more effective
ones early after treatment initiation.
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